Does Blue Cross Blue Shield (Federated) Cover Tresiba (Insulin Degludec)?

What Is Tresiba and Why Do Patients Seek It?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours in most adults. [1] The FDA approved both the U-100 and U-200 formulations on September 25, 2015, for glycemic control in adults with type 1 or type 2 diabetes mellitus. [2] Patients and clinicians often pursue Tresiba specifically because its flat pharmacokinetic profile is associated with fewer nocturnal hypoglycemic episodes compared with insulin glargine U-100.

The landmark DEVOTE trial (N=7,637) published in the New England Journal of Medicine demonstrated that degludec produced a 40% lower rate of severe nocturnal hypoglycemia versus glargine U-100 (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001 for superiority) while remaining non-inferior for major adverse cardiovascular events (MACE). [3] That hypoglycemia advantage is precisely why patients who have experienced nighttime lows on glargine argue for Tresiba coverage. [4]

The American Diabetes Association 2024 Standards of Care note that "ultra-long-acting insulin analogs (degludec, glargine U-300) have lower within-person variability and reduce hypoglycemia risk compared to NPH and glargine U-100." [5] That guideline language becomes important when building a prior authorization or appeal argument.

List price runs approximately $510 per month for five FlexTouch pens at U-100 concentration. Without insurance or a savings program, annual cost approaches $6,120. [6] The gap between list price and cash-pay options (roughly $35 per month with the Novo Nordisk savings card for eligible commercially insured patients) creates a meaningful access problem when coverage is denied. [7]

How Blue Cross Blue Shield (Federated) Structures Its Formulary for Basal Insulins

BCBS Federated plans do not operate from a single national drug formulary. Coverage is administered through individual state affiliates. A federal employee enrolled through the BCBS Federal Employee Program (FEP) faces different formulary rules than a commercial PPO member through BCBS of Illinois or BCBS of Texas. That distinction matters for every step of the prior authorization and appeal process.

Across most BCBS commercial plans, basal insulins are organized into three functional tiers. [8] Insulin NPH (human insulin isophane) typically sits at Tier 1 or Tier 2 as a preferred generic-equivalent option. Insulin glargine U-100 (Basaglar or authorized generic lantus) is usually Tier 2. Tresiba, being a non-preferred brand, lands on Tier 3 or Tier 4 on the majority of BCBS commercial formularies reviewed by the HealthRX pharmacy team.

Tier placement directly determines cost-sharing. A Tier 3 assignment typically means a $60 to $100 copay per fill on standard PPO plans, while a Tier 4 placement can mean 30% to 50% coinsurance with no cap until the out-of-pocket maximum is met. Patients should pull the current year's Summary of Benefits and Coverage (SBC) from their MyBlueCross portal and search for "Preferred Brand" and "Non-Preferred Brand" rows to confirm actual cost-sharing before initiating a prescription. [9]

The BCBS FEP plan, which covers approximately 5.5 million federal employees and annuitants, maintains its own separate formulary managed through FEP Blue Pharmacy. [10] FEP Blue Standard and FEP Blue Basic place most non-preferred brands including Tresiba in a tier requiring prior authorization and step therapy, mirroring the commercial plan structure.

Prior Authorization Criteria for Tresiba on BCBS Plans

Prior authorization (PA) is required on most BCBS Federated plans for Tresiba. The PA process generally requires clinical documentation submitted by the prescribing provider. Approval timelines run 3 to 5 business days for standard reviews and 24 to 72 hours for urgent reviews. [11]

Standard PA criteria across BCBS commercial affiliates typically include all of the following:

1. A confirmed diagnosis of type 1 or type 2 diabetes mellitus supported by HbA1c documentation.
2. Attestation that the patient is not using Tresiba for weight loss or any off-label purpose.
3. Documentation of a clinical reason why a preferred formulary basal insulin (glargine U-100 or detemir) is inadequate or contraindicated. Acceptable reasons include documented recurrent severe nocturnal hypoglycemia on glargine U-100 (typically defined as two or more events within 90 days) or a clinician attestation that glycemic variability on preferred agents has resulted in emergency care. [12]
4. In most plans, evidence of a prior 30-day to 90-day trial of at least one preferred basal insulin (see Step Therapy section below).

The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Type 2 Diabetes Management Algorithm states that "basal insulin analogs with a lower hypoglycemia risk profile should be prioritized in patients with a history of severe or nocturnal hypoglycemia." [13] Citing that language explicitly in the PA letter strengthens the medical necessity argument.

Providers submit PA requests through Availity (the standard BCBS portal), by fax to the plan's pharmacy benefit manager (commonly Prime Therapeutics for many BCBS plans), or through the prescribing EHR's integrated PA module. If the prescriber documents two or more nocturnal hypoglycemic events on glargine within the prior 90 days along with an HbA1c value, approval rates increase substantially. [14]

Step Therapy Requirements Before Tresiba Is Approved

Step therapy, sometimes called "fail-first," requires patients to try and document inadequacy of a cheaper preferred drug before the plan will pay for the requested medication. BCBS Federated plans almost universally apply step therapy to Tresiba for type 2 diabetes patients. The requirements are somewhat less stringent for type 1 patients who can demonstrate hypoglycemia risk. [15]

Typical step therapy sequence for type 2 diabetes:

• Step 1: Insulin glargine U-100 (Basaglar biosimilar or authorized generic) for a minimum of 30 days, titrated per ADA/EASD consensus guidelines. [16]
• Step 2: If glycemic targets are not met or documented hypoglycemia occurs, insulin detemir may be required as a second step on some plans before Tresiba is approved.
• Step 3: Tresiba approved if Step 1 (and possibly Step 2) fails per documented clinical criteria.

For type 1 patients, many BCBS plans waive or shorten the step requirement if the prescriber documents that the patient has already failed glargine U-100 prior to the current insurance enrollment period. That "prior trial" exception is worth pursuing. [17]

Step therapy exemption laws vary by state. As of 2024, 33 states plus the District of Columbia have enacted step therapy reform legislation requiring insurers to provide an exemption when a patient has previously tried the required drug or when the required drug is contraindicated. [18] Federal employees under FEP are governed by federal law, not state step therapy statutes, so FEP members cannot rely on state exemption laws. [19]

Keeping a hypoglycemia log (date, time, glucose value, symptoms, any emergency care) for 30 to 60 days before submitting a PA request gives the prescriber quantitative evidence to satisfy step therapy exemption criteria without requiring a new glargine trial. [20]

What Happens When BCBS Denies Tresiba Coverage

A denial notice from BCBS must state the specific clinical or formulary reason for the denial. Read that letter closely. Common denial reasons include: the drug is not on the formulary, step therapy was not completed, or medical necessity documentation was insufficient. Each reason has a specific rebuttal strategy. [21]

Under the Employee Retirement Income Security Act (ERISA), employer-sponsored health plans must allow at least one internal appeal. The appeal must be filed within the deadline stated on the denial letter, typically 180 days. For urgent medical situations, expedited appeal decisions are required within 72 hours. [22]

Internal Appeal Process:

1. Obtain the denial letter and the plan's specific clinical criteria (request the "coverage determination criteria" document in writing).
2. Have the prescriber draft a detailed appeal letter citing DEVOTE trial data [3], ADA 2024 Standards of Care hypoglycemia guidance [5], and AACE 2023 algorithm language. [13]
3. Attach all supporting records: HbA1c values, hypoglycemia incident logs, any emergency department or urgent care visits related to hypoglycemia.
4. Submit through the plan's formal appeal portal or by certified mail.

If the internal appeal fails, federal law requires access to an Independent Review Organization (IRO) for external review. The IRO decision is binding on the plan for most employer-sponsored plans. [23] State insurance department complaints are a parallel option for fully insured (non-ERISA) plans. [24]

Novo Nordisk's Patient Assistance Program (PAP), called the NovoCare Patient Assistance Program, provides free Tresiba to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the Federal Poverty Level). [25] This can serve as a bridge while an appeal is pending.

Cost Reduction Options While Navigating Coverage

Even with active insurance, patients can reduce out-of-pocket costs through several mechanisms. Each carries eligibility restrictions.

The Novo Nordisk Tresiba savings card allows commercially insured patients to pay as little as $35 per month. The card cannot be used by patients enrolled in Medicare, Medicaid, or any other federal or state government-funded health program. [7] Patients with BCBS commercial plans (not FEP) are generally eligible. BCBS FEP members are federal employees, and the FEP program's status under federal contracting rules may affect savings card eligibility; patients should verify directly with Novo Nordisk at 1-833-NOVO-411.

GoodRx and similar pharmacy discount platforms list insulin degludec U-100 (5 pack) at approximately $290 to $380 per month as a cash-pay price at major pharmacy chains, which is lower than the list price but substantially higher than the savings card rate. [26] GoodRx pricing cannot be combined with insurance; the patient must choose one or the other for each fill.

The American Diabetes Association maintains a resource page on insulin affordability that lists state-specific programs including emergency supply laws in 22 states that cap emergency insulin out-of-pocket costs at $35 for a 30-day supply. [27]

How to Talk to Your Prescriber About Strengthening a Tresiba PA

Patients often assume their doctor's office handles all PA paperwork automatically. In practice, PA success rates correlate strongly with the completeness of documentation the provider submits. [28] The following specific steps help.

Ask the provider to include in the PA letter:

• HbA1c values from the past 6 months with dates.
• A description of at least two nocturnal hypoglycemic episodes documented in the medical record, including glucose meter readings below 54 mg/dL (the ADA threshold for level 2 hypoglycemia). [5]
• Reference to the DEVOTE trial result showing a 40% reduction in severe nocturnal hypoglycemia with degludec versus glargine U-100. [3]
• The specific ADA 2024 language recommending agents with lower hypoglycemia risk for patients with hypoglycemia history. [5]
• Confirmation that the requested indication is glycemic control, not weight loss.

Endocrinologists who regularly manage insulin-dependent patients often have templates for Tresiba PAs. If the primary care provider lacks a template, the patient can request a referral to endocrinology specifically to support the PA process. [29]

Clinical Evidence Supporting Tresiba Over Preferred Formulary Agents

Insurers must weigh clinical evidence when evaluating PA appeals. Three trial-level findings are particularly useful for Tresiba appeals.

DEVOTE (N=7,637, NEJM 2017): Degludec was non-inferior to glargine U-100 for MACE (hazard ratio 0.91 to 95% CI 0.78 to 1.06) in patients with type 2 diabetes at high cardiovascular risk. Severe hypoglycemia occurred in 4.9% of degludec patients versus 6.6% of glargine patients (rate ratio 0.60 for nocturnal severe hypoglycemia, P<0.001). [3]

BEGIN Basal-Bolus Type 1 (N=629, Diabetes Care 2012): In type 1 patients, degludec produced comparable HbA1c reductions to glargine U-100 with a 25% lower rate of nocturnal confirmed hypoglycemia (rate ratio 0.75 to 95% CI 0.59 to 0.96, P<0.021). [30]

SWITCH 2 (N=721, Lancet Diabetes Endocrinology 2017): In a crossover trial of type 2 patients at risk for hypoglycemia, degludec reduced the rate of overall symptomatic hypoglycemia by 30% versus glargine U-100 (rate ratio 0.70 to 95% CI 0.61 to 0.80, P<0.0001). [31]

These three trials collectively support the argument that Tresiba is not merely a "me-too" basal insulin but offers a clinically meaningful reduction in hypoglycemia burden for patients with documented prior episodes. Citing all three in an appeal letter provides a body of evidence that an IRO reviewer must address. [32]

Specific Situations Where BCBS Is More Likely to Approve Tresiba

Certain clinical scenarios carry higher approval rates than others. Based on published PA criteria across BCBS affiliates and FDA label language, the following situations tend to support faster or first-try approval. [33]

Type 1 diabetes with documented hypoglycemia unawareness: Hypoglycemia unawareness (impaired awareness of hypoglycemia, IAH) is a recognized contraindication to continuing agents with higher hypoglycemia rates. The FDA Tresiba label explicitly notes the drug's reduced within-day variability as a pharmacokinetic advantage. [2] BCBS plans are more likely to grant PA exceptions for IAH patients.

Patients recently discharged after a hypoglycemia-related hospitalization: A hospital admission or emergency department visit for severe hypoglycemia creates an objective record of treatment failure on the prior agent. That record is difficult for a plan to dismiss during internal review.

Pediatric patients (age 1 and older): The FDA approved degludec for pediatric use in patients aged 1 year and older in 2019. [2] Many BCBS plans have separate PA criteria for pediatric diabetes management that may be less restrictive for ultra-long-acting agents when a pediatric endocrinologist is the prescribing provider.

Patients with renal impairment: Degludec does not require dose adjustment for renal impairment per FDA labeling, whereas some preferred agents require more careful titration. [2] Documenting chronic kidney disease (CKD) stage 3b or higher alongside hypoglycemia history may support a medical necessity argument.

Checking Your Specific BCBS Plan Before Prescribing

Because BCBS operates as a federation of independent state affiliates, no single coverage rule applies universally. The fastest way to verify current Tresiba coverage for a specific patient is a three-step check that takes under 10 minutes. [34]

1. Log into the member portal at the patient's specific BCBS affiliate website and use the formulary search tool. Search for "insulin degludec" or "Tresiba." The result will show tier placement, PA requirement, and any step therapy flag for the current plan year.
2. Call the pharmacy benefits number on the back of the insurance card and ask specifically: "Is PA required for Tresiba (NDC 00169-2600-15 for U-100 FlexTouch 5-pack), and what are the step therapy requirements?"
3. Have the prescriber's office run a real-time eligibility and PA check through Availity or CoverMyMeds before the patient leaves the office, so any PA barriers are identified before the patient attempts to fill.

A denied fill at the pharmacy counter is recoverable, but it delays therapy. Proactive verification at the prescribing visit eliminates that delay. [35]

The ADA recommends that clinicians "assess the patient's financial situation and insurance coverage before prescribing insulin, and use the least expensive effective therapy when cost is a limiting factor." [5] When Tresiba's clinical profile is the reason for choosing it over glargine, documenting that rationale in the chart note before submitting a PA creates a paper trail that supports every subsequent step, from initial PA through external appeal.